Anne K Monroe1, Lindsey P Happ1, Nabil Rayeed2, Yan Ma3, Maria J Jaurretche1, Arpi S Terzian1, Kevin Trac1, Michael A Horberg4, Alan E Greenberg1, Amanda D Castel1. 1. Department of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA. 2. Cerner Corporation, Kansas City, Missouri, USA. 3. Department of Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA. 4. Mid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States, Rockville, Maryland, USA.
Abstract
BACKGROUND: Using the results of a site assessment survey performed at clinics throughout Washington, DC, we studied the impact of clinic-level factors on antiretroviral therapy (ART) initiation and viral suppression (VS) among people living with human immunodeficiency virus (HIV; PLWH). METHODS: This was a retrospective analysis from the District of Columbia (DC) Cohort, an observational, clinical cohort of PLWH from 2011-2018. We included data from PLWH not on ART and not virally suppressed at enrollment. Outcomes were ART initiation and VS (HIV RNA < 200 copies/mL). A clinic survey captured information on care delivery (eg, clinical services, adherence services, patient monitoring services) and clinic characteristics (eg, types of providers, availability of evenings/weekends sessions). Multivariate marginal Cox regression models were generated to identify those factors associated with the time to ART initiation and VS. RESULTS: Multiple clinic-level factors were associated with ART initiation, including retention in care monitoring and medication dispensing reviews (adjusted hazard ratios [aHRs], 1.34 to 1.40; P values < .05 for both). Furthermore, multiple factors were associated with VS, including retention in HIV care monitoring, medication dispensing reviews, and the presence of a peer interventionist (aHRs, 1.35 to 1.72; P values < .05 for all). In multivariable models evaluating different combinations of clinic-level factors, enhanced adherence services (aHR, 1.37; 95% confidence interval [CI], 1.18-1.58), medication dispensing reviews (aHR, 1.22; 95% CI, 1.10-1.36), and the availability of opioid treatment (aHR, 1.26; 95% CI, 1.01-1.57) were all associated with the time to VS. CONCLUSIONS: The observed association between clinic-level factors and ART initiation/VS suggests that the presence of specific clinic services may facilitate the achievement of HIV treatment goals.
BACKGROUND: Using the results of a site assessment survey performed at clinics throughout Washington, DC, we studied the impact of clinic-level factors on antiretroviral therapy (ART) initiation and viral suppression (VS) among people living with human immunodeficiency virus (HIV; PLWH). METHODS: This was a retrospective analysis from the District of Columbia (DC) Cohort, an observational, clinical cohort of PLWH from 2011-2018. We included data from PLWH not on ART and not virally suppressed at enrollment. Outcomes were ART initiation and VS (HIV RNA < 200 copies/mL). A clinic survey captured information on care delivery (eg, clinical services, adherence services, patient monitoring services) and clinic characteristics (eg, types of providers, availability of evenings/weekends sessions). Multivariate marginal Cox regression models were generated to identify those factors associated with the time to ART initiation and VS. RESULTS: Multiple clinic-level factors were associated with ART initiation, including retention in care monitoring and medication dispensing reviews (adjusted hazard ratios [aHRs], 1.34 to 1.40; P values < .05 for both). Furthermore, multiple factors were associated with VS, including retention in HIV care monitoring, medication dispensing reviews, and the presence of a peer interventionist (aHRs, 1.35 to 1.72; P values < .05 for all). In multivariable models evaluating different combinations of clinic-level factors, enhanced adherence services (aHR, 1.37; 95% confidence interval [CI], 1.18-1.58), medication dispensing reviews (aHR, 1.22; 95% CI, 1.10-1.36), and the availability of opioid treatment (aHR, 1.26; 95% CI, 1.01-1.57) were all associated with the time to VS. CONCLUSIONS: The observed association between clinic-level factors and ART initiation/VS suggests that the presence of specific clinic services may facilitate the achievement of HIV treatment goals.
Authors: Michael Alan Horberg; Leo Bartemeier Hurley; Michael Jonah Silverberg; C James Kinsman; Charles Patrick Quesenberry Journal: J Acquir Immune Defic Syndr Date: 2007-04-15 Impact factor: 3.731
Authors: Melanie A Thompson; Michael J Mugavero; K Rivet Amico; Victoria A Cargill; Larry W Chang; Robert Gross; Catherine Orrell; Frederick L Altice; David R Bangsberg; John G Bartlett; Curt G Beckwith; Nadia Dowshen; Christopher M Gordon; Tim Horn; Princy Kumar; James D Scott; Michael J Stirratt; Robert H Remien; Jane M Simoni; Jean B Nachega Journal: Ann Intern Med Date: 2012-03-05 Impact factor: 25.391
Authors: Alan E Greenberg; Harlen Hays; Amanda D Castel; Thilakavathy Subramanian; Lindsey Powers Happ; Maria Jaurretche; Jeff Binkley; Mariah M Kalmin; Kathy Wood; Rachel Hart Journal: J Am Med Inform Assoc Date: 2015-12-31 Impact factor: 4.497
Authors: Frederick L Altice; R Douglas Bruce; Gregory M Lucas; Paula J Lum; P Todd Korthuis; Timothy P Flanigan; Chinazo O Cunningham; Lynn E Sullivan; Pamela Vergara-Rodriguez; David A Fiellin; Adan Cajina; Michael Botsko; Vijay Nandi; Marc N Gourevitch; Ruth Finkelstein Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Thomas P Giordano; Fehmida Visnegarwala; A Clinton White; Catherine L Troisi; Ralph F Frankowski; Christine M Hartman; Richard M Grimes Journal: AIDS Care Date: 2005-08
Authors: Baligh R Yehia; Kelly A Gebo; Perrin B Hicks; P Todd Korthuis; Richard D Moore; Michelande Ridore; William Christopher Mathews Journal: AIDS Patient Care STDS Date: 2008-12 Impact factor: 5.078
Authors: Esther A N Engelhard; Colette Smit; Pythia T Nieuwkerk; Peter Reiss; Frank P Kroon; Kees Brinkman; Suzanne E Geerlings Journal: AIDS Care Date: 2016-03-13
Authors: Ingrid T Katz; Annemarie E Ryu; Afiachukwu G Onuegbu; Christina Psaros; Sheri D Weiser; David R Bangsberg; Alexander C Tsai Journal: J Int AIDS Soc Date: 2013-11-13 Impact factor: 5.396
Authors: Lindsey Powers Happ; Anne K Monroe; Heather A Young; Yan Ma; Alan E Greenberg; Michael A Horberg; Amanda D Castel Journal: J Acquir Immune Defic Syndr Date: 2020-09-01 Impact factor: 3.731
Authors: Maria Jaurretche; Matthew Levy; Amanda D Castel; Lindsey Powers Happ; Anne K Monroe; Karen F Wyche Journal: J Racial Ethn Health Disparities Date: 2021-03-15
Authors: Jenevieve Opoku; Rupali K Doshi; Amanda D Castel; Ian Sorensen; Michael Horberg; Adam Allston; Michael Kharfen; Alan E Greenberg Journal: JMIR Public Health Surveill Date: 2020-04-15